TY  - JOUR
AU  - Hunter, Samuel F
AU  - Aburashed, Rany A
AU  - Alroughani, Raed
AU  - Chan, Andrew
AU  - Dive, Dominique
AU  - Eichau, Sara
AU  - Kantor, Daniel
AU  - Kim, Ho Jin
AU  - Lycke, Jan
AU  - Macdonell, Richard A L
AU  - Pozzilli, Carlo
AU  - Scott, Thomas
AU  - Sharrack, Basil
AU  - Wiendl, Heinz
AU  - Chung, Luke
AU  - Daizadeh, Nadia
AU  - Baker, Darren P
AU  - Vermersch, Patrick
AU  - CARE-MS I, CARE-MS II, CAMMS03409, and TOPAZ Investigators
PY  - 2021
DO  - 10.1007/s40120-021-00262-3
SN  - 2193-8253
UR  - http://hdl.handle.net/10668/18038
T2  - Neurology and therapy
AB  - In the 2-year CARE-MS trials (NCT00530348; NCT00548405) in patients with relapsing-remitting multiple sclerosis, alemtuzumab showed superior efficacy versus subcutaneous interferon beta-1a. Efficacy was maintained in two consecutive extensions...
LA  - en
KW  - Alemtuzumab
KW  - Confirmed disability improvement
KW  - Confirmed disability worsening
KW  - Disease-modifying therapy
KW  - Expanded Disability Status Scale
KW  - Functional systems
KW  - Multiple sclerosis
TI  - Confirmed 6-Month Disability Improvement and Worsening Correlate with Long-term Disability Outcomes in Alemtuzumab-Treated Patients with Multiple Sclerosis: Post Hoc Analysis of the CARE-MS Studies.
TY  - research article
VL  - 10
ER  -